Gilead Sciences’ Livdelzi achieves 75% ALP normalisation response in Phase 3 IDEAL trial
Gilead's Livdelzi achieved 75.4% ALP normalisation in Phase 3 IDEAL versus 16.1% with placebo. Examine its clinical and regulatory impact.
Pharma & Biotech